-
Mashup Score: 0
Multiple myeloma (MM) incidence is markedly higher in blacks compared with whites, which may be related to a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS). Our objective was to define the prevalence and risk factors of MGUS in a large cohort representative of the US …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy - 4 month(s) ago
Introduction: With the availability of multiple therapy classes targeting BCMA for multiple myeloma (MM), data are needed to understand effective treatment (tx)
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 33
Program: Oral and Poster Abstracts Session: 653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I Hematology Disease Topics & Pathways: Diseases, therapy sequence, Therapies, Lymphoid Malignancies Larysa Sanchez, MD 1 *, Carolina Schinke, MD 2, Amrita Krishnan, MD 3, Jésus G Berdeja, MD 4, Niels W.C.J van de Donk, MD, PhD 5 *, María Victoria Mateos, MD, PhD 6, Ajai Chari, MD 7 *, Samir Parekh, MD 8, Tarek H. Mouhieddine, MD 9, Sundar Jagannath, MD 8, Nizar J Bahlis, MD 10, Cyrille Touzeau, MD,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Free Light Chain Assay Drift: Potential for Misdiagnosis? - PubMed - 5 month(s) ago
Free Light Chain Assay Drift: Potential for Misdiagnosis?
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3
TPS8075 Background: Standard of care for SMM includes active monitoring until progression to multiple myeloma (MM); however, recent evidence suggests pts with high-risk features may benefit from early treatment. DARA is a human IgGκ monoclonal antibody targeting CD38 that is approved as monotherapy for relapsed/refractory MM (RRMM) or in combination with standard of care for RRMM or newly diagnosed MM. Results from the phase 3 COLUMBA study showed that DARA SC demonstrated similar efficacy to intravenous (IV) DARA but with a lower rate of infusion-related reactions and shorter administration time. Based on the promising single-agent activity observed with IV DARA in intermediate- or high-risk SMM pts during the phase 2 CENTAURUS study, we hypothesized that DARA SC may delay progression to MM versus active monitoring in pts with high-risk SMM. Methods: AQUILA is an ongoing, randomized, open-label, multicenter phase 3 study of DARA SC versus active monitoring in pts with high-risk SMM. D
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Congophilic Fibrillary Glomerulonephritis: A Case Series - PubMed - 11 month(s) ago
The congophilic properties of organized fibrillary deposits should not be solely relied on in differentiating fibrillary GN from renal amyloidosis. Mass spectrometry and DNAJB9 immunohistochemistry can be useful in making this distinction.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Amgen.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Sequencing of nontransplant treatments in multiple myeloma patients with active disease - 2 year(s) ago
Abstract. The approval of several different classes of drugs in recent years has resulted in a dramatic expansion of treatment options for multiple myeloma pati
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Abstracts & Posters | ASCO Annual Meeting - 2 year(s) ago
Your PrivacyASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with…
Source: conferences.asco.orgCategories: Latest Headlines, Oncologists1Tweet
@ManniMD1 @Drjhoffmanmiami I think the testing for MGUS was done systematically in the NHANES study. More info here in the original prevalence of MGUS in the NHANES publication by @DrOlaLandgren https://t.co/wsHHtvFSv2 https://t.co/isQZhf8GuQ